KRON - Kronos Bio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-140M

Cash

219.5M

Avg Qtr Burn

-18.97M

Short % of Float

6.22%

Insider Ownership

16.23%

Institutional Own.

56.54%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KB-0742 (CDK9 Inhibitor) Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lanraplenib (SYK Inhibitor) +gilteritinib Details Blood cancer, Leukemia, Acute myeloid leukemia, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Entospletinib (SYK Inhibitor) Details HOXA9/MEIS1-high AML (Acute myeloid leukemia)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.